115 related articles for article (PubMed ID: 31687847)
1. Treatment characteristics for nonmetastatic castration-resistant prostate cancer in the United States, Europe and Japan.
Shah R; Botteman M; Waldeck R
Future Oncol; 2019 Dec; 15(35):4069-4081. PubMed ID: 31687847
[No Abstract] [Full Text] [Related]
2. Assessment of Factors Predicting Disease Progression in Japanese Patients With Non-Metastatic Castration-resistant Prostate Cancer.
Miyake H; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2020 Feb; 40(2):1101-1106. PubMed ID: 32014960
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns and characteristics of European patients with castration-resistant prostate cancer.
Sternberg CN; Baskin-Bey ES; Watson M; Worsfold A; Rider A; Tombal B
BMC Urol; 2013 Nov; 13():58. PubMed ID: 24206580
[TBL] [Abstract][Full Text] [Related]
4. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
5. A retrospective study on the incidence, management and risk factors of skin rash in patients with advanced prostate cancer in Japan.
De Moor R; Koroki Y; Wu DB; Yu DY; Tohyama M; Ohyama C
BMC Urol; 2023 Apr; 23(1):73. PubMed ID: 37118710
[TBL] [Abstract][Full Text] [Related]
6. Estimating high-risk castration resistant prostate cancer (CRPC) using electronic health records.
Hernandez RK; Cetin K; Pirolli M; Quigley J; Quach D; Smith P; Stryker S; Liede A
Can J Urol; 2015 Aug; 22(4):7858-64. PubMed ID: 26267023
[TBL] [Abstract][Full Text] [Related]
7. Real-world homologous recombination repair mutation testing in metastatic castration-resistant prostate cancer in the USA, Europe and Japan.
Leith A; Ribbands A; Kim J; Last M; Barlow S; Yang L; Ghate SR
Future Oncol; 2022 Mar; 18(8):937-951. PubMed ID: 35043687
[TBL] [Abstract][Full Text] [Related]
8. Clinical drivers for imaging testing in non-metastatic castration-resistant prostate cancer in clinical practice: Results of the IDENTIFICA study.
Cózar Olmo JM; Carballido Rodríguez J; Rubio-Briones J; Useros Rodríguez E; Muñoz Del Toro J; García García-Porrero Á; Juárez-Soto Á;
Actas Urol Esp (Engl Ed); 2021 Apr; 45(3):198-206. PubMed ID: 33558084
[TBL] [Abstract][Full Text] [Related]
9. Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.
Sourbeer KN; Howard LE; Moreira DM; Amarasekara HS; Chow LD; Cockrell DC; Hanyok BT; Pratson CL; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Hernandez RK; Freedland SJ
J Urol; 2015 Apr; 193(4):1232-8. PubMed ID: 25463986
[TBL] [Abstract][Full Text] [Related]
10. Impact of age, comorbidity, and PSA doubling time on long-term competing risks for mortality among men with non-metastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Freedland SJ; DeHoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Daskivich TJ
Prostate Cancer Prostatic Dis; 2019 May; 22(2):252-260. PubMed ID: 30279582
[TBL] [Abstract][Full Text] [Related]
11. Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?
Ito K; Kimura T; Onuma H; Tabata R; Shimomura T; Miki K; Tomita M; Egawa S
Prostate; 2018 May; 78(7):498-505. PubMed ID: 29473179
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry.
Akaza H; Procopio G; Pripatnanont C; Facchini G; Fava S; Wheatley D; Leung KC; Butt M; Silva A; Castillo L; Karavasilis V; Ӧzatılgan A; Hitier S; Ecstein-Fraisse EB; Ӧzgüroḡlu M
J Glob Oncol; 2018 Sep; 4():1-12. PubMed ID: 30260754
[TBL] [Abstract][Full Text] [Related]
13. Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective.
Suzuki K; Grillo V; Chen Y; Singh S; Ledesma DA
JCO Glob Oncol; 2021 Feb; 7():302-310. PubMed ID: 33617305
[TBL] [Abstract][Full Text] [Related]
14. Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research.
Penson DF; Lin DW; Karsh L; Quinn DI; Shevrin DH; Shore N; Symanowski JT; Brown B; Forer D; Wong EK; Flanders SC
Future Oncol; 2016 Dec; 12(23):2689-2699. PubMed ID: 27528114
[TBL] [Abstract][Full Text] [Related]
15. Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database.
Dambal S; Howard LE; Allott EH; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
J Urol; 2020 Jan; 203(1):120-127. PubMed ID: 31430247
[TBL] [Abstract][Full Text] [Related]
16. Management of nonmetastatic castration-resistant prostate cancer.
Traboulsi SL; Saad F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):366-371. PubMed ID: 30015690
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer in Latin America: Challenges and Recommendations.
Reis RBD; Alías-Melgar A; Martínez-Cornelio A; Neciosup SP; Sade JP; Santos M; Villoldo GM
Cancer Control; 2020; 27(1):1073274820915720. PubMed ID: 32316767
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns in patients with advanced (stage III-IV) ovarian cancer in the USA and Europe.
Hall JP; Chang J; Moon R; Higson O; Byrne K; Doherty JP; Cappelleri JC
Future Oncol; 2020 May; 16(15):1013-1030. PubMed ID: 32326746
[No Abstract] [Full Text] [Related]
19. Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study.
Boegemann M; Khaksar S; Bera G; Birtle A; Dopchie C; Dourthe LM; Everaert E; Hatzinger M; Hercher D; Hilgers W; Matus G; Alvarez LG; Antoni L; Lukac M; Pissart G; Robinson P; Elliott T
BMC Cancer; 2019 Jan; 19(1):60. PubMed ID: 30642291
[TBL] [Abstract][Full Text] [Related]
20. Non-metastatic castration resistant prostate cancer: a review of current and emerging medical therapies.
Alpajaro SIR; Harris JAK; Evans CP
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):16-23. PubMed ID: 30115959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
